Related Experiment Video

Updated: May 16, 2026

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?

Eva Dreussi1, Paola Biason, Giuseppe Toffoli

  • 1Experimental & Clinical Pharmacology Unit, Centro di Riferimento Oncologico - National Cancer Institute, Via Franco Gallini, 2, 33081 Aviano, Italy.

Pharmacogenomics
|November 15, 2012
PubMed

Insights

Genetic variations in microRNAs (miRNAs) are emerging as key pharmacogenomic markers for predicting cancer treatment response and toxicity. Studying these genetic polymorphisms offers new insights for personalized cancer therapy.

Area of Science:

  • Pharmacogenomics
  • Cancer Biology
  • Molecular Genetics

Background:

  • Pharmacogenomic research has identified genetic biomarkers for drug efficacy and toxicity.
  • Genetic polymorphisms in microRNA (miRNA) related genes are increasingly recognized as significant pharmacogenomic markers in oncology.
  • miRNAs are small non-coding RNAs that regulate gene expression post-transcriptionally.

Purpose of the Study:

  • To review recent findings on genetic polymorphisms in miRNA machinery as novel pharmacogenomic markers in cancer.
  • To explore the potential of these markers for personalized cancer therapy.
  • To provide an overview of future perspectives in this rapidly evolving field.

Main Methods:

  • Literature review of recent studies on miRNA genetic polymorphisms and their role in cancer pharmacogenomics.
  • Analysis of the impact of these polymorphisms on drug metabolism, transport, and mechanism of action.
  • Synthesis of current knowledge on miRNA biogenesis and function in the context of cancer treatment.

Main Results:

  • Genetic polymorphisms in miRNA encoding genes, their targets, and maturation factors are associated with cancer treatment outcomes.
  • These polymorphisms can influence mRNA and protein expression levels, affecting drug response.
  • The study of these variations offers innovative insights into pharmacogenomic applications in oncology.

Conclusions:

  • Genetic polymorphisms in the miRNA pathway represent promising biomarkers for personalized cancer therapy.
  • Further research in this area can lead to improved prediction of treatment toxicity and efficacy.
  • Understanding these genetic factors is crucial for advancing precision medicine in oncology.

More Related Videos

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.